Drug
Fulzerasib clinical trials
Also written GFH925 and IBI351.
- studies test it
- 8
- open now
- 3
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the fulzerasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 3
Innovent Biologics (Suzhou) Co. Ltd. (4) · Genfleet Therapeutics (Shanghai) Inc. (1) · Sun Yat-sen University (1) · Shanghai Chest Hospital (1) · Jianxing He (1)
Often tested with
Tested in the same studies.
Cetuximab (1) · Esomeprazole (1) · Itraconazole (1) · Dextromethorphan (1) · Proteasomal Ubiquitin Receptor ADRM1 (1) · Tunlametinib (1) · Ivonescimab (1)
Studies
Open first, then newest update. How each study uses fulzerasib is read from its arms, and is right about nine times in ten.
Testing it · 8
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLCRecruitingPhase 2Jianxing HeNCT07492342Written as fulzerasib
- Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07463677Written as Tunlametinib + Fulzerasib
- A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C MutationNot yet recruitingPhase 2Shanghai Chest HospitalNCT06936644Written as IBI351+AK112
- A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C MutationsCompletedPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT05005234Written as GFH925
- A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C MutationCompletedPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT05756153Written as GFH925
- A Study of [14C]IBI351 in Healthy SubjectsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05626179Written as [14C] IBI351
- A Study of IBI351 in Healthy SubjectsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05688124Written as IBI351
- A Study of IBI351 in Healthy SubjectsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05699993Written as IBI351
Given in every arm · 2 — fulzerasib is usual care beside what is tested
- Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C MutationRecruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05504278Written as IBI351
- A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal CancerTerminatedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05497336Written as IBI351
As the comparator · 1 — what is tested is compared with fulzerasib
Codes
What other systems call fulzerasib · ClinicalTrials.gg INT015248
- UNII (FDA) 6D5B7F245WFULZERASIBOne source FDA
- NCI Thesaurus C199055FulzerasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6D5B7F245W | FULZERASIB | One source FDA |
| NCI Thesaurus | C199055 | Fulzerasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.